In males androgens mediate growth and development of male sex organs and the development and maintenance of secondary sex characteristics. Androgens also generally increase protein anabolism and decrease protein catabolism. Exogenous administration of androgens results in activation of feedback mechanisms resulting in reduced endogenous testosterone production.
Methyltestosterone is a synthetic androgen receptor agonist. Methyltestosterone is a testosterone mimic used for treating men with testosterone deficiency. In addition it is used in the treatment of breast cancer in postmenopausal women as an antineoplastic agent. Methyltestosterone is a testosterone derivative bearing a methyl group at the 17 alpha position that functionally increases bioavailability. Methyltestosterone binds cytosolic androgen receptors and the ligand-receptor complex functions as a transcription factor regulating expression of androgen-responsive genes. Androgen responsive genes are responsible for growth and development of male sex organs and secondary sexual characteristics. Anabolic agents such as methyltestosterone stimulate anabolism and inhibit catabolism and thus stimulate the development of muscle mass, strength and power.
Methyltestosterone is one of many synthetic androgen therapeutics. Overall use of exogenous androgens such as methyltestosterone is limited and carefully monitored as significant undesirable side effects such prostate growth can occur. More recently non-steroidal androgen receptor modulators have been developed that can activate androgen receptor but are not reduced to dihydrotestosterone or aromatized to estradiol and thus do not exhibit undesirable off-target effects.






